KYDES products are developed from currently approved drug compounds and FDA approved excipients using our proprietary technologies. The products will be manufactured to meet or exceed Current Good Manufacturing Practices (CGMP) Guidelines set forth by the FDA and other Regulatory Agencies. The products listed in the menu above are in various stages of development.
Click on the products below for details.
|KY1101 & KY1102||KY1103||KY1104||KY1105||KY1106||KY1107|
Drugs are the mainstay of pain management and drug treatment for pain represents a tremendous growth area. In 2005, the market totaled $19 billion in the U.S. and $30 billion worldwide. This represents an approximately 6% compounded annual growth rate in the U.S. since 2001. The worldwide market is expected to grow to $35 billion by 2010. In 2005, analgesics were the fourth most prescribed medication in the U.S., with over 246 million prescriptions.
KYDES’s products, KY001 & KY002, are designed to address the pain and inflammation of the joint with minimal systemic toxicity. The potential total market for these products in North America alone is vast; the projected number of arthritis patients who can benefit from treatment with this product is estimated to be over 20 million annually. Formulation development is near completion and a patent application for KY001 was filed in the US. Manufacturing and Regulatory activities are underway to obtain approval for KY002 as topical OTC pain medication outside US.